This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory
by Zacks Equity Research
Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.
Becton, Dickinson Focuses on Medication Management, Stock Up
by Zacks Equity Research
Management at Becton, Dickinson and Company (BDX) has been focusing on strengthening its portfolio for long.
Here's Why You Should Offload Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.
Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.
5 MedTech Momentum Picks Investors Will Love
by Zacks Equity Research
In a volatile political environment, seasoned investors should focus on momentum stocks as winning bets to tide over the uncertainty.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat
by Zacks Equity Research
Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.
Abiomed's Latest Regulatory Progress Boosts Impella Line
by Zacks Equity Research
We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.
Fresenius Medical Opens Manufacturing Plant in Malaysia
by Zacks Equity Research
Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.
Invacare (IVC) Introduces TDX SP2 Power Wheelchair Globally
by Zacks Equity Research
Invacare Corporation's (IVC) newly launched TDX SP2 Power Wheelchair would greatly help in capturing the highly competitive global wheelchair market.
NxStage Medical Partners Dialyze Direct for On-Site Dialysis
by Zacks Equity Research
The latest development will lend NxStage Medical (NXTM) a competitive edge in the hemodialysis dialysis market. The company will leverage on its System One platform for treating patients with ESRD.
PRA Health Sciences (PRAH) Prices Secondary Stock Offering
by Zacks Equity Research
PRA Health Sciences' (PRAH) move to procure funds through secondary offering is likely to enhance its bottom line and shareholders' returns.
Varian Medical (VAR) Signs Distribution Deal with Bionix
by Zacks Equity Research
Varian Medical's (VAR) new distribution agreement with Bionix Radiation Therapy would strengthen its radiotherapy business in North America.
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
by Zacks Equity Research
Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.
Fresenius Medical Inks $2B Deal to Take Over NxStage Medical
by Zacks Equity Research
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
Luminex (LMNX) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Luminex's (LMNX) assay business will be its key driver over the long term. The FDA go-ahead for Luminex ARIES Bordetella and ARIES C. Difficile assay were the key highlights of the second quarter.
Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top
by Zacks Equity Research
Evolent Health's (EVH) strong rise in the number of members on its platform was the key highlight of the second quarter.
Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Envision Healthcare's (EVHC) second-quarter results were positively impacted by strong Physician Services segment.
NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS
by Megan Sanks
German dialysis provider Fresenius Medical Care (FMS) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. (NXTM) for $2 billion.
Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.
DexCom (DXCM) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
DexCom, Inc. (DXCM) was a big mover last session, as the company saw its shares rise nearly 7% on the day after the company reported better-than-expected third quarter, 2017 results.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Revenues Lag
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted strong numbers in the second quarter on growth in its Consulting Services, MWI Animal Health and World Courier businesses.
Fresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.